U.S. flag An official website of the United States government
  1. Home
  2. Drugs
  3. Drug Safety and Availability
  4. Postmarket Drug Safety Information for Patients and Providers
  5. Ampyra (dalfampridine) Information
  1. Drug Safety and Availability

Ampyra (dalfampridine) Information

Ampyra (dalfampridine) Information

Ampyra (dalfampridine) was approved on January 22, 2010, to improve walking in patients with multiple sclerosis (MS). 

To report any unexpected adverse or serious events associated with the use of this drug, please contact the FDA MedWatch program using the information at the bottom of this page.

Related Information

Approval History and Labeling from Drugs@FDA